BTIG analyst David Larsen raised the price target on CryoPort (NASDAQ: CYRX) to $17.00 (from $15.00) while maintaining a Buy rating.

The analyst comments "On Monday, 5/4/26 AMC, CYRX reported good 1Q:26 results. Total revenue of $47.8M +16.5% y/y exceeded BTIG / consensus estimates of $44.8M / $44.9M and adjusted EBITDA of ($0.6M) also exceeded BTIG / consensus estimates of ($1.5M) / ($1.5M). The revenue beat came from both business segments, with Product revenue of $20.9M up +15% y/y (vs. our prior $19.1M E) and Services revenue of $26.9M up +18% y/y (vs. our $25.7M E). Top-line growth lead to the EBITDA beat in the quarter, and CYRX remains on-track to return to positive EBITDA in the second-half of the year. We were encouraged to see the company increase full-year 2026E guidance for revenue as a result of the quarter. Management highlighted on the call that there is still some uncertainty in the global macro environment, but our view is that the pharma environment continues to improve, demand is picking up, and CYRX is turning the corner. After what seems like a period of years of highly erratic and inconsistent demand, it appears like the market has returned to growth mode."